Cargando…

A Randomized Multicenter Study Comparing a Tacrolimus-Based Protocol with and without Steroids in HCV-Positive Liver Allograft Recipients

Allograft reinfection with hepatitis C virus (HCV) occurs universally in liver transplant recipients. Corticosteroids can contribute to HCV recurrence. This randomized study evaluated HCV recurrence in HCV-positive liver allograft recipients using steroid-free immunosuppression. All patients receive...

Descripción completa

Detalles Bibliográficos
Autores principales:	Neumann, Ulf, Samuel, Didier, Trunečka, Pavel, Gugenheim, Jean, Gerunda, Giorgio Enrico, Friman, Styrbjörn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3368368/ https://www.ncbi.nlm.nih.gov/pubmed/22690326 http://dx.doi.org/10.1155/2012/894215

Ejemplares similares

Long-term, Prolonged-release Tacrolimus-based Immunosuppression in De Novo Liver Transplant Recipients: 5-year Prospective Follow-up of Patients in the DIAMOND Study
por: Friman, Styrbjörn, et al.
Publicado: (2021)

Renal Function in De Novo Liver Transplant Recipients Receiving Different Prolonged‐Release Tacrolimus Regimens—The DIAMOND Study
por: TruneČka, P., et al.
Publicado: (2015)

Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes
por: Manousou, Pinelopi, et al.
Publicado: (2014)

Recipient Hyperbilirubinemia May Reduce Ischemia-Reperfusion Injury but Fails to Improve Outcome in Clinical Liver Transplantation
por: Oltean, Mihai, et al.
Publicado: (2016)

Immunological Monitoring of Renal Transplant Recipients to Predict Acute Allograft Rejection Following the Discontinuation of Tacrolimus
por: Kreijveld, Ellen, et al.
Publicado: (2008)

Open-Label, Randomized Study of Transition From Tacrolimus to Sirolimus Immunosuppression in Renal Allograft Recipients
por: Tedesco-Silva, Helio, et al.
Publicado: (2016)

The Impact of Single Nucleotide Polymorphisms on the Pharmacokinetics of Tacrolimus in Kidney Allograft Recipients of Northern-West, Iran
por: Jabbari Hagh, Elaheh, et al.
Publicado: (2023)

Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients
por: Armando, Calogero, et al.
Publicado: (2019)

Conversion from Tacrolimus to Cyclosporine A Improves Glucose Tolerance in HCV-Positive Renal Transplant Recipients
por: Handisurya, Ammon, et al.
Publicado: (2016)

Transplantation of Renal Allografts From Organ Donors Reactive for HCV Antibodies to HCV-Negative Recipients: Safety and Clinical Outcome
por: Nowak, Knut Michael, et al.
Publicado: (2016)

Erratum to “Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients”
por: Calogero, Armando, et al.
Publicado: (2019)

A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation
por: Wlodarczyk, Zbigniew, et al.
Publicado: (2012)

Impact of Acute Rejection on Kidney Allograft Outcomes in Recipients on Rapid Steroid Withdrawal
por: Heilman, R. L., et al.
Publicado: (2011)

The Effect of Donor Age and Recipient Characteristics on Renal Outcomes in Patients Receiving Prolonged-Release Tacrolimus After Liver Transplantation: Post-Hoc Analyses of the DIAMOND Study
por: Trunečka, Pavel, et al.
Publicado: (2019)

Influence of CYP3A5 polymorphism on tacrolimus drug dosing in Indian renal allograft recipients: initial experience
por: Patel, Mohan, et al.
Publicado: (2014)

Prospective Controlled Protocol for Three Months Steroid Withdrawal with Tacrolimus, Basiliximab, and Mycophenolate Mofetil in Renal Transplant Recipients
por: Oh, Chang-Kwon, et al.
Publicado: (2012)

Influence of CYP3A5 and ABCB1 Polymorphism on Tacrolimus Drug Dosing in South Indian Renal Allograft Recipients
por: Fernando, M. Edwin, et al.
Publicado: (2019)

The Association between CDKAL1 Gene rs10946398 Polymorphism and Post-Transplant Diabetes in Kidney Allograft Recipients Treated with Tacrolimus
por: Dziedziejko, Violetta, et al.
Publicado: (2023)

Mechanistic analyses in kidney transplant recipients prospectively randomized to two steroid free regimen—Low dose Tacrolimus with Everolimus versus standard dose Tacrolimus with Mycophenolate Mofetil
por: Traitanon, Opas, et al.
Publicado: (2019)

Antiphospholipid Syndrome in Renal Allograft Recipients—A Long-Term Multicenter Analysis
por: Furmańczyk-Zawiska, Agnieszka, et al.
Publicado: (2023)

Utilization of COVID-19 allografts without transmission to recipients in liver transplantation
por: Whitrock, J., et al.
Publicado: (2023)

Tacrolimus trough levels in kidney transplant recipients
por: Hwang, Young Hui, et al.
Publicado: (2021)

Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus
por: Nishioka, Shun, et al.
Publicado: (2021)

Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients
por: Johansson, Inger, et al.
Publicado: (2015)

Efficacy and safety of prolonged‐release tacrolimus in stable pediatric allograft recipients converted from immediate‐release tacrolimus – a Phase 2, open‐label, single‐arm, one‐way crossover study
por: Rubik, Jacek, et al.
Publicado: (2019)

Experience with tacrolimus in children with steroid-resistant nephrotic syndrome
por: Butani, Lavjay, et al.
Publicado: (2009)

A Randomized Pharmacokinetic Study of Generic Tacrolimus Versus Reference Tacrolimus in Kidney Transplant Recipients
por: Alloway, R R, et al.
Publicado: (2012)

Development and effects of tacrolimus-loaded nanoparticles on the inhibition of corneal allograft rejection
por: Wu, Qianni, et al.
Publicado: (2019)

Clinical Pharmacokinetics of Tacrolimus in Iranian Liver Transplant Recipients
por: Nasiri-Toosi, Zahra, et al.
Publicado: (2014)

Gout Due to Tacrolimus in a Liver Transplant Recipient
por: Afridi, Summia Matin, et al.
Publicado: (2019)

Peripheral blood lymphocyte subsets change after steroid withdrawal in renal allograft recipients: a prospective study
por: Llinàs-Mallol, Laura, et al.
Publicado: (2019)

Transplantation of a Liver Allograft From a Hepatitis C Virus Seropositive Donor With Previous Sustained Virologic Response to an Uninfected Recipient Suffering Steroid Refractory Acute Graft Rejection With No Evidence of HCV Transmission
por: Mitchell, Robert A., et al.
Publicado: (2018)

Comparison of the effects of standard vs low‐dose prolonged‐release tacrolimus with or without ACEi/ARB on the histology and function of renal allografts
por: Cockfield, Sandra M., et al.
Publicado: (2019)

Zygomycosis in a renal allograft recipient
por: Lakshminarayana, G., et al.
Publicado: (2009)

Mycobacterial disease in renal allograft recipients
por: Ardalan, Mohammad-Reza
Publicado: (2013)

Chromoblastomycosis in a renal allograft recipient
por: Sooraj, Y. S., et al.
Publicado: (2013)

Efficacy and safety of tacrolimus in de novo pediatric transplant recipients randomized to receive immediate‐ or prolonged‐release tacrolimus
por: Vondrak, Karel, et al.
Publicado: (2019)

Limited sampling strategies for estimation of tacrolimus exposure in kidney transplant recipients receiving extended‐release tacrolimus preparation
por: El‐Nahhas, Toqa, et al.
Publicado: (2021)

Epidermal Cysts in a Tacrolimus Treated Renal Transplant Recipient
por: Ahn, In Su, et al.
Publicado: (2011)

Systematic conversion to generic tacrolimus in stable kidney transplant recipients
por: Rosenborg, Staffan, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_6dt8g3dtle8dj6uk3hpfnj0kt9